EAU 25 | Professors Samson Chan and Junlong Zhuang : PARPi Treatment Shows Initial Efficacy in mHSPC, Advancing Precision Therapy for Prostate Cancer

EAU 25 | Professors Samson Chan and Junlong Zhuang : PARPi Treatment Shows Initial Efficacy in mHSPC, Advancing Precision Therapy for Prostate Cancer

PARP inhibitors (PARPi) have ushered in a new era of precision treatment for prostate cancer. Multiple studies have confirmed that patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair deficiency mutations (HRRm) can benefit from this therapeutic approach. At the recently held 2025 European Association of Urology(EAU25) conference , a single-arm Phase II PROact study conducted by Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, was reported. The study demonstrated promising preliminary efficacy and safety of the combination of olaparib, abiraterone, and prednisone in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). UroStream was honored to invite Prof. Junlong Zhuang from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, and Prof. Samson Chan from Department of Surgery, Tuen Mun Hospital, HONG KONG, to engage in a dialogue and share the latest advancements and clinical experiences in precision therapy for prostate cancer.
Research Progress丨Analysis of Platinum Intolerance and Treatment Outcomes in First-Line Treatment of Advanced Urothelial Carcinoma Patients

Research Progress丨Analysis of Platinum Intolerance and Treatment Outcomes in First-Line Treatment of Advanced Urothelial Carcinoma Patients

Advanced urothelial carcinoma (UC) patients have a poor prognosis with a low 5-year survival rate. Since the 1980s, platinum-based chemotherapy has been the standard first-line therapy for locally advanced or metastatic UC (la/mUC), but the benefits are limited. The real-world tolerance and treatment outcomes of platinum therapy remain unclear. This year's study analyzed data from advanced UC patients in the United States. This article summarizes and organizes the findings for our readers.
ASCO GI 2025 | Dr. Anna Dorothea Wagner:Dual-Target Therapy Shows No Survival Benefit in HER2-Positive Gastric Cancer

ASCO GI 2025 | Dr. Anna Dorothea Wagner:Dual-Target Therapy Shows No Survival Benefit in HER2-Positive Gastric Cancer

The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. One of the most closely watched presentations at the conference was the release of results from the EORTC-1203—INNOVATION trial (Abstract LBA331), capturing the attention of oncologists worldwide. Oncology Frontier had the exclusive opportunity to interview Dr. Anna Dorothea Wagner, a medical oncologist from Lausanne University Hospital in Switzerland, to discuss the study’s findings. Below is a summary of our conversation.